secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0000950170-23-069381
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports clinical data on oral CDK9 inhibitor voruciclib at ASH2023; safety profile well-tolerated
--------------------------------------------------------------------------------

- Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.
- On-target Mcl-1 and RNA Pol II p-S2 reductions demonstrated in correlative pharmacodynamic studies.
- In AML monotherapy: 1 patient achieved morphologic leukemia-free state; 9 had stable disease (2 for ≥3 months).
- In B-cell malignancies: 4 patients had stable disease with tumor size decrease.
- Combination with venetoclax ongoing; no DLTs or overlapping toxicity; anti-tumor activity observed with multiple patients on therapy ≥4 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/0000950170-23-069381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017023069381/meip-20231211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer